Today is FOUR HUNDRED DAYS into human trial of AVA6000.
#AVCT started at 80mg/m2 and are now at a quite incredible 200mg/m2.
Equivalent to 135mg/m2 of Dox.
They are yet to find a MTD.
Orphan Designation from FDA.
SP = 111.7p.
(-)6.13% YTD for 400 days and no MTD.
What’s crazy about this SP being below placing at this stage is AVCT isn’t going to have any more data which disproves or proves the platform by this stage.
If you are Takeda and you are in the data room, you aren’t thinking ‘I really want to see the impact of 200mg vs 160mg’.